Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Down 79.0% in November

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) saw a large drop in short interest in November. As of November 15th, there was short interest totalling 774,700 shares, a drop of 79.0% from the October 31st total of 3,690,000 shares. Currently, 3.5% of the shares of the stock are sold short. Based on an average daily volume of 15,910,000 shares, the short-interest ratio is currently 0.0 days.

Tevogen Bio Price Performance

TVGN stock traded down $0.03 during mid-day trading on Wednesday, reaching $1.31. 615,608 shares of the stock traded hands, compared to its average volume of 4,948,997. Tevogen Bio has a 52-week low of $0.26 and a 52-week high of $21.09. The stock’s fifty day moving average is $1.25 and its 200-day moving average is $0.89.

Insider Activity

In other news, insider Neal Flomenberg sold 1,078,600 shares of the firm’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the completion of the transaction, the insider now owns 4,254,302 shares in the company, valued at approximately $6,891,969.24. This trade represents a 20.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 56.60% of the company’s stock.

Institutional Trading of Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. acquired a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned approximately 0.13% of Tevogen Bio at the end of the most recent quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.